Ventilatory Function Abnormalities and Associated Factors Among Adult Survivors of Multidrug-Resistant Tuberculosis in Douala, Cameroon: A Cross-Sectional Study
Anomalies de la Fonction Ventilatoire et Facteurs Associés chez les Adultes Guéris de la Tuberculose Multirésistante à Douala, Cameroun : une Étude Transversale
DOI:
https://doi.org/10.5281/zenodo.18600011Keywords:
Abnormal ventilator pattern, pulmonary function, multidrugresistant tuberculosis, DoualaAbstract
Introduction. Pulmonary lesions resulting from multidrug-resistant tuberculosis (MDR-TB) often cause significant structural damage, potentially leading to long-term ventilatory problems. This study aimed to characterize these abnormal breathing patterns and identify associated factors in patients successfully treated for MDR-TB in Douala. Patients and Methods. This was a cross-sectional and analytical study conducted between November 2022 and May 2023, involving adults who completed MDR-TB treatment at a specialized center in Douala between 2015 and 2021. Results. A total of 141 adult patients were included. The mean age ± standard deviation was 40.62 ± 12.89 years, with a male predominance (57.4%). People who were married or in a couple represented 44% of cases. The informal sector was the most represented workfield (65.24%). Exposure to biomass smoke was reported primarily from charcoal (65.2%). The types of tuberculosis included new cases (39.0%), relapse (35.46%), failure (21.27%), and treatment interruption (4.25%). Among the included participants, 44% (62) had a ventilatory disorder. Among these, 26.4% presented with an obstructive ventilatory disorder, 16.5% with a restrictive ventilatory disorder, and 8.3% with a mixed ventilatory disorder. Multivariate analysis allowed for the estimation of associations for clinically relevant factors, such as biomass smoke exposure (aOR:1.46; 95% CI:0.56–3.80) and HIV status (aOR:0.70; 95% CI:0.20–2.80). Conclusion. This study reveals a high prevalence of ventilatory disorders in adults successfully treated for multidrug-resistant tuberculosis. This underscores the importance of incorporating the assessment of these abnormalities into the clinical evaluation and long-term care of these patients.
References
1. Tuberculose multirésistante : épidémiologie et facteurs de risqueMultidrug-resistant tuberculosis: Epidemiology and risk factors. Rev Pneumol Clin. 2015;71:233‑41.
2. Piubello A. Guide pratique pour la prise en charge de la tuberculose résistante: 2018. Paris: Union internationale contre la tuberculose et les maladies respiratoires; 2018.
3. World Health Organization. Tuberculose [Internet]. Genève : WHO ; cité le 18 juin 2024. Disponible sur : https://www.who.int/fr/news-room/fact-sheets/detail/tuberculosis
4. World Health Organization. Augmentation du nombre de cas de tuberculose et de décès dus à la maladie pendant la pandémie de COVID-19 [Internet]. Genève: WHO; 2022 [cité 18 juin 2024]. Disponible sur: https://www.who.int/fr/news/item/27-10-2022-tuberculosis-deaths-and-disease-increase-during-the-covid-19-pandemic
5. World Health Organization. Global tuberculosis report 2023 [Internet]. Genève: WHO; 2023 [cité 18 juin 2024]. Disponible sur: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2023
6. Douala [Internet]. Wikiwand; cité le 8 août 2024. Disponible sur : https://www.wikiwand.com/fr/Douala
7. Graham BL, Steenbruggen I, Miller MR, Barjaktarevic IZ, Cooper BG, Hall GL, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J Respir Crit Care Med. 2019;200:e70 88.
8. Godoy MD, Mello FC, Lopes AJ, Costa W, Guimarães FS, Pacheco AG, et al. The Functional Assessment of Patients With Pulmonary Multidrug-Resistant Tuberculosis. Respir Care. 2012;57:1949 54.
9. ingla R, Mallick M, Mrigpuri P, Singla N, Gupta A. Sequelae of pulmonary multidrug-resistant tuberculosis at the completion of treatment. Lung India. 2018;35:4.
10. De Vallière S, Barker RD. Residual lung damage after completion of treatment for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2004;8:767‑71.
11. Vashakidze SA, Kempker JA, Jakobia NA, Gogishvili SG, Nikolaishvili KA, Goginashvili LM, et al. Pulmonary function and respiratory health after successful treatment of drug-resistant tuberculosis. Int J Infect Dis. 2019;82:66‑72.
12. Auld SC, Maenetje P, Ravimohan S, Weissman D, Ncube I, Mlotshwa M, et al. Declines in Lung Function After Antiretroviral Therapy Initiation in Adults With Human Immunodeficiency Virus and Tuberculosis: A Potential Manifestation of Respiratory Immune Reconstitution Inflammatory Syndrome. Clin Infect Dis. 2020;70:1750‑3.
13. Nuwagira E, Stadelman A, Baluku JB, Rhein J, Byakika-Kibwika P, Mayanja H, et al. Obstructive lung disease and quality of life after cure of multi-drug-resistant tuberculosis in Uganda: a cross-sectional study. Trop Med Health. 2020;48:34.
14. Muñoz-Torrico M, Cid-Juárez S, Gochicoa-Rangel L, Torre-Bouscolet L, Salazar-Lezama MA, Villarreal-Velarde H, et al. Functional impact of sequelae in drug-susceptible and multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2020;24:700‑5.
15. Essebaa S, Ben Saad S, Ben Mansour A, Channoufi A, Naffeti O, Bel Hadj S, Daghfous H, Tritar F. Tuberculose multirésistante guérie : fin d’une tragédie ou début d’une autre ? Rev Mal Respir Actual. 2021; 13(1):233.
16. Perea L, Faner R, Chalmers JD, Sibila O. Pathophysiology and genomics of bronchiectasis. Eur Respir Rev. 2024;33(240055). Disponible sur : https://www.researchgate.net/publication/381981648_Pathophysiology_and_genomics_of_bronchiectasis
17. Masson E. Profil fonctionnel respiratoire des dilatations des bronches [Internet]. EM-Consulte; [cité 19 juin 2024]. Disponible sur: https://www.em-consulte.com/article/1343164/profil-fonctionnel-respiratoire-des-dilatations-de
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Endale Mangamba Laurent-Mireille, Mbele Onana Charles Lebon, Akono Mbou Prudence, Teyim Pride Mbuh, Wandji Ngoupeyou Irène-Adeline, Kuaban Alain, Mbatchou Ngahane Bertrand Hugo
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License CC BY-NC-ND 4.0 that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work
